5 assets in Oral Cavity Carcinoma

Therapeutic assets addressing Oral Cavity Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Oral Cavity Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Oral Cavity Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pembrolizumab Oral Cavity Carcinoma	VLP Therapeutics	P1	CC (43)
Vrp-Encapsulated Sarna Encoding Il-12 Oral Cavity Carcinoma	VLP Therapeutics	P1	CC (43)
92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER Oral Cavity Carcinoma	Masonic Cancer Center, University of Minnesota	N/A	D (30)